Wind turbine producer Goldwind returned and 36Kr Fund also invested as rocket technology developer LandSpace secured $43.2m in a series B-plus round.

PellePharm has signed a $760m agreement with Leo Pharma to create therapies for skin cancers, with Leo investing $70m in a first tranche and securing an option to wholly acquire PellePharm.

Intel Capital and Airbus Ventures have both reinvested in the computer vision system developer, in a round that featured undisclosed auto component producers.

Ping An has led a $47.3m investment in Finleap through its Global Voyager Fund, joining a list of shareholders that already included Hannover Re and Signal Iduna.

Novartis Venture Fund returned to reinvest in inflammatory disease drug developer Inflazome as part of its $45.6m series B round.

The geolocation software provider received $42.5m in a round that included GM Ventures and Salesforce Ventures, taking its total funding to about $83m.

Inflammatory disease drug developer Inflazome, based on research at University of Queensland and Trinity College Dublin, has added $45.6m in series B capital to its coffers.

Novartis and Access Industries unit Clal Biotechnology Industries both took part in the neurological disorder drug developer's series B round.

Intel Capital led a series B round for the artificial intelligence-based processor developer, bringing its overall funding to $120m.

Liberty Global and Shanda Group were among the investors that have backed Mojo Vision’s invisible computing platform with $50m of capital.